• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MedImmune

MedImmune

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers

    Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers

  2. Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

    Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

  3. Research and Markets: Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

    Research and Markets: Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

  4. Research and Markets: Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2014

    Research and Markets: Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2014

  5. Research and Markets: Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014

    Research and Markets: Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014

  6. Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch

    Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch

  7. Research and Markets: PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 for the $23 Billion Industry

    Research and Markets: PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 for the $23 Billion Industry

  8. Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants

    Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants

  9. Morningstar Indexes: Weekly Market Report

    Week ending April 27: Quarterly earnings continue to boost market's spirits. 

  10. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.